24/7 Market News Snapshot 13 January, 2025 – Standard BioTools Inc. Common Stock (NASDAQ:LAB)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:LAB) are discussed in this article.
Standard BioTools Inc. (NASDAQ:LAB) experienced a notable surge today, opening at $1.85 and currently trading around $1.938, which represents an impressive increase of approximately 18.90%. The stock closed at $1.630 in the previous session, demonstrating strong bullish momentum. With trading volume reaching 1.18 million shares, investor interest appears to be heightened. This upward price movement could indicate positive market sentiment or favorable news catalysts. Monitoring the stock’s support and resistance levels will be crucial for making informed predictions, as maintaining a price above $1.90 may suggest a continuation of this bullish trend, while a decline below $1.85 could lead to profit-taking or a potential reversal.

In a significant development, Standard BioTools has announced preliminary and unaudited revenue results for the fourth quarter and the entirety of 2024, signaling a remarkable achievement amid challenging market conditions. The company expects to report approximately $46.5 million in revenue for the fourth quarter, with full-year revenue anticipated at around $174 million. Michael Egholm, PhD, Chief Executive Officer, expressed pride in the team’s commitment, highlighting that they successfully met the top end of their revised annual guidance.

Dr. Egholm emphasized the critical role of the Standard BioTools Business Systems (SBS) in enhancing operational efficiency and achieving sustained improvements in revenue, particularly in high-margin offerings. The successful implementation of SBS has led to significant reductions in operating expenses, preparing the company for continued advancement.

Standard BioTools plans to release a comprehensive report of its fourth-quarter and full-year financial results later this quarter, alongside strategic insights for 2025. Focused on empowering researchers to drive innovative medicine development, the company remains steadfast in its mission to enhance patient outcomes and deliver long-term value for shareholders. Exciting opportunities for growth and innovation lie ahead in the evolving healthcare landscape.

Related news for (LAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.